We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nobel Prize Winner to Address Annual Pathology Meeting

By Labmedica staff writers
Posted on 20 Sep 2006
The pathologist's role in patient safety, advances in molecular pathology for early disease diagnoses, and the newest clinical laboratory tests are among the many issues to be explored at the 2006 Annual Meeting of The American Society for Clinical Pathology (ASCP), October 18-22, in Las Vegas (Nevada, USA). More...
Nobel Prize winner Louis J. Ignarro, Ph.D., of the University of California, Los Angeles (UCLA, USA), will give the opening keynote address.

Dr. Ignarro will present a historical perspective of his research, including his experiences in Stockholm as he received the Nobel Prize. His experimentation led to the discovery that nitric oxide is the neurotransmitter responsible for penile erection. Dr. Ignarro's research made it possible for medical professionals to understand what protects the cardiovascular system against pathologic conditions, such as hypertension and atherosclerosis. His studies have also resulted in a new understanding of cardiovascular system pathology, and contributed to the development of a variety of pharmaceuticals, including Viagra (sildenafil, Pfizer).

On October 20, Ralph L. Nachman, M.D., professor and chair, department of medicine Weill Cornell Medical College (New York, NY, USA), will give the scientific keynote address entitled "To Clot or Not to Clot: a Clinical Challenge.” He will talk about how chronologic advances, new discoveries in molecular genetics, and serendipity have furthered the understanding of coagulation and fibrinolytic systems. Dr. Nachman will address hypercoagulable states from their molecular biology to their clinical consequences.

Ralph H. Hruban, M.D., professor, pathology and oncology, The Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins University (Baltimore, MD, USA), will present the Arthur Purdy Stout Keynote address on October 21. His lecture is entitled "Tumors of the Pancreas: From Genes to Diagnostic Pathology.” He will present an overview of the pathobiology of pancreatic neoplasia with emphasis on the application of the latest technologies to diagnose pancreatic pathology.

At the meeting, pathologists will learn about other new topics and concepts, take interactive and dynamic courses, and share ideas and strategies to deal with the toughest challenges in pathology. There will be numerous exhibits displaying state-of-the-art technology, products, and services for pathologists and laboratory professionals.



Related Links:
American Society for Clinical Pathology

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.